Current Report Filing (8-k)
November 03 2022 - 04:19PM
Edgar (US Regulatory)
false000126099000012609902022-11-032022-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of report (Date of earliest event reported)
November 3, 2022
Oncternal Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
Delaware
|
|
000-50549
|
|
62-1715807
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
12230 El Camino Real
Suite 230
San
Diego,
CA
92130
(858)
434-1113
|
|
|
(Address and zip code; telephone number, including area code, of
registrant’s principal executive offices)
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2. below):
|
|
|
☐
|
Written communication pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share
|
|
ONCT
|
|
The Nasdaq Stock Market, LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02. Results of Operations and Financial
Condition.
On November 3, 2022, Oncternal Therapeutics, Inc., issued a press
release announcing its financial results for the third quarter
ended September 30, 2022. A copy of this press release is attached
hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liability of that section, nor shall it
be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, except as expressly set forth
by specific reference in such filing to this Current Report on Form
8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Oncternal Therapeutics, Inc.
|
|
|
|
|
Date: November 3, 2022
|
By:
|
/s/ Richard G. Vincent
|
|
|
|
|
Name: Richard G. Vincent
|
|
|
|
|
Title: Chief Financial Officer
|
2
Oncternal Therapeutics (NASDAQ:ONCT)
Historical Stock Chart
From Feb 2023 to Mar 2023
Oncternal Therapeutics (NASDAQ:ONCT)
Historical Stock Chart
From Mar 2022 to Mar 2023
